Risgal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Risgal

Quick Facts

Property Description
Active Ingredient Risperidone (INN)
Forms Tablets, Oral Solution, Injectable Suspension
Pharmacological Class Second-Generation Antipsychotic (SGA)
General Purpose Management of severe mental disorders
Origin Synthetic Compound (Benzisoxazole Derivative)

What Type of Medicine is Risgal?

Risgal is a prescription psychotropic medicine whose single active component is Risperidone. This compound is classified as an antipsychotic agent belonging specifically to the second-generation antipsychotics (SGAs), commonly known as atypical antipsychotics. Risperidone is a wholly synthetic compound, a derivative of the benzisoxazole chemical class. This classification is clinically recognized for its profile of balanced neurochemical action, distinguishing it from older antipsychotic therapies.

The SGA classification establishes the medicine's foundational role in psychiatric disorder management, where it is used to help modulate overactive signaling pathways in the brain. This means the drug is supported by pharmacological data confirming its capacity to stabilize severe thought, mood, and behavioral disruptions.

Composition, Forms, and General Therapeutic Goal

As a single-ingredient product, Risgal’s therapeutic effect is derived entirely from the pharmacological action of Risperidone, combined with pharmaceutical excipients that form the inert vehicle. Risperidone is available in several dosage forms to accommodate patient needs, including oral tablets, an oral solution, orally disintegrating tablets (ODT), and a long-acting injectable suspension. The versatility of these forms ensures appropriate administration based on individual clinical need.

The fundamental therapeutic goal of Risgal is the stabilization of mood and thought processes in individuals with severe mental disorders. By exerting a regulating influence on key neurochemical messengers, the medication is used to help patients manage symptoms associated with conditions that affect their perception of reality. Use of this medication is established for the symptomatic management of certain central nervous system disorders.

Regulatory References

  1. National Institutes of Health/MedlinePlus

What side effects are possible with Risgal?

Possible Side Effects and Safety Information

The official safety information for Risgal (Risperidone) organizes possible adverse effects by how frequently they occur and the body system affected, based on regulatory classifications established by authorities like the EMA and FDA.

Classification Examples of Documented Adverse Reactions
Very Common (1/10) Parkinsonism (movement-related symptoms), Headache, Insomnia
Common (1/100 to <1/10) Somnolence (drowsiness), Dizziness, Weight increased, Nausea, Constipation, Upper respiratory tract infection, Anxiety

Adverse reactions span multiple System-Organ Classes, including the Nervous System (e.g., extrapyramidal symptoms, seizures), Metabolism and Nutrition (e.g., weight gain, metabolic changes), and Endocrine Disorders (Hyperprolactinemia, which may persist during chronic use).

Serious Adverse Reactions

Official labeling highlights several serious adverse reactions, including the potential for Increased Mortality in Elderly Patients with Dementia-Related Psychosis (a Boxed Warning in the FDA label) and the risk of Cerebrovascular Adverse Events (CVAEs), such as stroke, in that population. Other rare but serious reactions include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD), and significant Metabolic Changes (Hyperglycemia/Diabetes Mellitus). Events of Leukopenia, Neutropenia, and Agranulocytosis have also been reported.

Population and Timing Constraints

Safety notes specify caution for certain groups, including elderly patients and those with Renal or Hepatic Impairment. The risk of Orthostatic Hypotension (a drop in blood pressure upon standing) is noted to be highest during the initial dose titration period. The medicine has the official potential to impair judgment, thinking, and motor skills.

Overdose and Emergency Response

Overdose and When to Seek Help

Risgal is an opioid medication, and its use carries a risk of accidental or intentional overdose, which is a life-threatening medical emergency. Overdose occurs when a person takes a higher dose than their body can handle, primarily overwhelming the brain's ability to control breathing, which can lead to respiratory failure and potentially death.

Primary Overdose Presentations Symptoms and Manifestations
Central Nervous System Depression Unconsciousness or inability to awaken; extreme unresponsiveness.
Respiratory Depression Slowed or shallow breathing; difficulty breathing; gurgling or snoring sounds.
Circulatory/Skin Signs Lips or fingernails turning blue, purple, or gray; pale, clammy skin; limp body.

Immediate medical attention is required for any suspected overdose. Emergency action is critical to prevent fatal outcomes. In the event of a suspected overdose, call 911 immediately and administer an opioid overdose reversal medication (such as naloxone), if available, while waiting for emergency services to arrive. Overdose symptoms may return after the reversal medication's effect wears off, so monitoring and professional medical follow-up for several hours are essential. The risk of overdose is increased when the medication is taken in higher than prescribed doses or in combination with other Central Nervous System depressants, including alcohol or benzodiazepines. Special attention must be paid to dose calculations for specific populations, particularly children, to prevent accidental exposure to high concentrations.

Therapeutic Uses of Risgal

What Risgal Treats: Main Uses and Benefits

Risgal (Risperidone) may be part of symptomatic management across conditions involving certain symptoms of severe mental and behavioral disorders. Its therapeutic application focuses on managing heightened symptoms that create significant functional strain and patient distress.

The medication is considered relevant in clinical settings marked by conditions involving episodic or fluctuating manifestations, such as Schizophrenia, Bipolar I Disorder (for acute manic or mixed episodes), and Autistic Disorder (to address severe irritability). It is commonly used when groups of symptoms, such as hallucinations, delusions, severe irritability, or agitation, may become intense or disruptive.

This treatment supports clearer thinking and helps ease the intensity of disruptive experiences, which may assist with maintaining a sense of stability when symptoms are more noticeable. By addressing the pronounced symptoms, it contributes to easing the overall symptom load associated with heightened emotional and behavioral manifestations across adults, adolescents, and children (for specific indications).


Quick Fact: Relief for Behavioral Disruption

Symptom Type Condition Context Core Patient Benefit
Psychotic Symptoms Schizophrenia (acute/maintenance) Supports clearer perception
Mood Extremes Bipolar I Mania/Mixed Episodes Eases emotional burden/instability
Severe Irritability Autistic Disorder (pediatric) Assists with managing aggression

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The regulatory profile for the active ingredient in “Risgal” (known in official government sources as risperidone) defines specific populations for whom the medicine is restricted or prohibited.

Contraindicated and Restricted Use

Classification Population/Condition Regulatory Status
Absolute Exclusion Known hypersensitivity to the drug or its components. Contraindicated
Absolute Exclusion Elderly patients with dementia-related psychosis. Contraindicated (Increased mortality risk)
Conditional Use Severe renal or hepatic impairment. Restricted (Lower initial dosing required)
Use Not Established Pediatric patients below specific age limits. Restricted (Age dependent on indication)

Eligibility is defined by official age cut-offs, with use not established for schizophrenia patients under 13 years, bipolar mania under 10 years, and autism-associated irritability under 5 years. For pregnancy, use in the third trimester may cause temporary symptoms in newborns. Lactation is officially discouraged, although data suggests low levels in milk. Regulatory documents strictly prohibit use in populations where safety risks are clearly documented, such as in elderly patients with dementia-related psychosis, which is an explicit non-approved use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Risgal (Risperidone) around specific pharmacokinetic and pharmacodynamic patterns.

Documented Pharmacokinetic Interactions

The most significant interactions involve substances that modulate drug metabolism or transport, leading to altered plasma concentrations of the active moiety (Risperidone and 9-hydroxyrisperidone):

Substance Category Examples Official Regulatory Effect
Strong CYP2D6 Inhibitors Fluoxetine, Paroxetine Increases plasma concentrations of risperidone.
Strong CYP3A4 Inducers Carbamazepine Decreases plasma concentrations of the active moiety.
P-glycoprotein (P-gp) Modulators Itraconazole, Carbamazepine Officially alters systemic exposure (inhibitors increase, inducers decrease).
Non-Enzyme Modifiers Cimetidine, Ranitidine Increases the bioavailability of risperidone.

Pharmacodynamic & Substance Restrictions

Interactions involving combined physiological effects are also formally documented:

  • Centrally-Acting Drugs: Co-administration may result in additive Central Nervous System (CNS) effects.
  • Hypotensive Agents: The blood pressure-lowering effects of co-administered drugs may be enhanced.
  • Alcohol (Ethanol): Must be avoided due to the documented potential for enhanced CNS effects.
  • Oral Solution Restriction: The oral solution is officially documented as incompatible with cola or tea and should not be mixed with these beverages.

Population-Specific Note: Clearance of the active moiety is documented as decreased in patients with renal or hepatic impairment, which is a key exposure consideration in these populations.

Mechanism of Action

Blocking the Central IL-23 Inflammatory Signal

Risgal works by acting as a highly selective antagonist to the Interleukin-23 (IL-23) cytokine, a signaling protein in the body's immune system. The drug specifically binds to and neutralizes this molecular target, preventing IL-23 from activating its receptor on immune cells. This early step of molecular interference is essential for initiating the drug's downstream effects, which focus on reducing the intensity of downstream signal propagation.


Interrupting the Th17-Driven Inflammatory Cascade

The blockade of IL-23 fundamentally interrupts the entire IL-23/Th17 axis, a pathway associated with the sustained production of inflammatory mediators. By stopping the IL-23 signal, the drug limits the growth and activation of Th17 cells, which are the primary source of secondary inflammatory mediators like IL-17A and IL-22. This mechanistic action leads to a reduction in the presence of inflammatory mediators at the physiological level, contributing to a shift toward a lower concentration of pro-inflammatory cytokines in tissues.

Dosage and Administration Information

Administration Methods

Risgal is typically administered under the supervision of a healthcare professional. The method of administration depends on the specific formulation prescribed and the clinical setting.

General Usage Principles

When using this medication, it is important to maintain a consistent schedule as determined by a healthcare provider. The medication is designed to be integrated into a comprehensive treatment plan. Patients are encouraged to discuss the process of administration with their medical team to ensure they understand the routine and what to expect during each session.

Monitoring and Support

Regular follow-up appointments are a standard part of using Risgal. These sessions allow for the monitoring of the individual's response to the treatment. Healthcare providers may adjust the approach based on ongoing clinical observations and the patient's feedback regarding their progress.

Preparation

Before administration, healthcare providers ensure that the medication is at the correct temperature and that all necessary equipment is prepared according to clinical standards. Individuals receiving the medication should follow any specific pre-administration guidance provided by their clinic, such as dietary or hydration recommendations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Risgal

Evidence for Use in Schizophrenia

Research examining Risgal (risperidone) for Schizophrenia has focused on used in research exploring how symptoms change over time during periods of heightened activity and over longer stretches of time. Short-term studies, which were often randomized controlled trials (RCTs), was studied for how symptoms change over time. These trials typically observed adults and adolescents over periods lasting approximately four to nine weeks. Other research has also focused on long-acting injectable forms of Risgal and was monitored in trials exploring symptom patterns over several months. The results apply only to the populations studied, and there is limited information for long-term outcomes beyond one to two years.


Evidence for Use in Bipolar I Disorder (Manic or Mixed Episodes)

For Bipolar I Disorder, Risgal was studied for managing acute manic or mixed episodes—conditions characterized by fluctuating or episodic manifestations. The primary evidence comes from short-term, randomized, placebo-controlled trials. Studies conducted during periods of increased symptom activity monitored outcomes describing episodic or acute changes in mood and behavior, typically over three to six weeks. The evidence is concentrated on how symptoms evolve in the observed populations during the acute phase. Consequently, data are still emerging regarding its use for long-term maintenance, and its role in monitoring long-term stability and recurrence over many years is not fully established based on the short-term trials alone.


What is Still Uncertain About Risgal Research

While research describes patterns related to short-term changes in symptoms across approved uses, several aspects remain uncertain. A primary limitation is that long-term outcomes are not fully established, as controlled follow-up durations were limited in many of the core efficacy studies. Additionally, comparative evidence is lacking in certain areas, and evidence quality varies across studies. Research provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain—about long-term outcomes.

Key Studies & References

  1. Risperidone for children and adolescents with autism spectrum disorder: a systematic review - Dove Medical Press
  2. Risperidone - StatPearls - NCBI Bookshelf - NIH

Frequently Asked Questions (FAQ)

Common questions about Risgal (FAQ)

Q: How quickly does Risgal start to work after the first dose?

A: Studies and official information indicate that the clinical effects of the long-acting injectable (LAI) form of Risgal may not be fully observed until approximately three weeks after the first injection. The initiation phase of the long-acting injection (LAI) regimen involves a period of overlap with oral medication, which is a key part of the official administration protocol. The oral forms of the medication are associated with symptom management over initial short-term trials lasting several weeks.


Q: What's the difference between Risgal and other similar mental health medications?

A: Risgal, which contains the active ingredient risperidone, is classified as a Second-Generation Antipsychotic (SGA), also known as an atypical antipsychotic. According to official regulatory documents, this class of medicine is generally differentiated from older antipsychotics by its balanced action on both dopamine and serotonin receptors in the brain.


Q: How long does Risgal stay in your system after stopping it?

A: The active components of Risgal have an elimination half-life of around 20 hours after administration. However, because the long-acting injectable (LAI) form is designed to release medication slowly over time, the drug's presence in the system is sustained for several weeks following the last injection.


Q: Do I need to take Risgal with food or on an empty stomach?

A: Official product information for the oral formulations of Risgal (tablets and solutions) indicates that they can be taken with or without food. This information primarily relates to the oral forms of the medication.


Q: Is it safe to take Risgal if I also take Tylenol or ibuprofen?

A: Official labeling focuses on interactions with prescription medications that strongly affect drug metabolism, central nervous system (CNS) function, or blood pressure. While these documents do not specifically list interactions with common over-the-counter pain relievers like Tylenol (acetaminophen) or ibuprofen, it is important that patients discuss all medications, including over-the-counter drugs, with a healthcare professional.


Q: Why do some people feel restless when taking Risgal?

A: Regulatory information reports that akathisia (a feeling of inner restlessness) and Parkinsonism (movement-related symptoms) are commonly observed adverse reactions in clinical trials.


Q: Can Risgal affect my ability to drive or operate machinery?

A: Official warnings advise that Risgal may impair an individual's judgment, thinking, and motor skills. Official guidance suggests that individuals should use caution when operating machinery or driving until they know how the medication may affect their motor skills and judgment.


Q: Does Risgal interact with alcohol, even small amounts?

A: Official labeling states that alcohol should be avoided while using Risgal. This is due to the potential for enhanced or additive central nervous system (CNS) effects that can occur when alcohol is combined with the medication.


Q: Can Risgal cause changes in my vision or eye problems?

A: Official documents report that visual disturbances and other vision problems have been noted as adverse reactions. Furthermore, certain rare but serious side effects, such as priapism (a prolonged erection) or movement disorders that affect the eyes, are also documented possibilities.


Q: What precautions should be taken before starting Risgal?

A: Official regulatory warnings advise taking certain precautions. This includes regular monitoring for metabolic changes like high blood sugar and undesirable weight gain. Monitoring of the complete blood count (CBC) may be recommended, particularly for patients with a history of low white blood cell count.


Q: Can Risgal be used for anxiety or just for psychosis?

A: The official regulatory indications state that Risgal is approved for the treatment of schizophrenia, acute manic or mixed episodes associated with Bipolar I Disorder, and irritability associated with autistic disorder. It is not formally indicated for the treatment of general anxiety disorders.


Q: Are there any specific supplements that interact badly with Risgal?

A: Regulatory documents detail interactions with certain prescription drugs that affect liver enzymes, specifically strong inhibitors of the CYP2D6 enzyme or strong inducers of the CYP3A4 enzyme. Since supplements can affect these same enzymes, patients are advised to discuss the full metabolic profile of any supplement with their healthcare professional.


Q: How often do people need blood tests when they are on Risgal?

A: According to the official safety information, patients with diabetes or those at risk for the condition may require regular glucose monitoring. Similarly, frequent monitoring of the complete blood count (CBC) may be needed, especially during the first few months, for patients with a known history of low white blood cell count.


Q: Is Risgal a habit-forming or addictive drug?

A: The active ingredient in Risgal is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). Its official regulatory labeling addresses dependence and abuse in this context.


Q: What is the average duration of treatment with Risgal?

A: Regulatory information indicates that the drug's effectiveness for maintenance treatment has been studied for extended periods beyond acute symptom management. While patients who respond well are often maintained on treatment, official guidance notes that the long-term benefits versus risks of continued use should be periodically evaluated.


Q: Do many patients successfully switch from a different drug to Risgal?

A: Official regulatory documentation states that there is no systematically collected data specifically addressing the successful switching of patients from other antipsychotics to Risgal, or using them at the same time.


Q: Are there known food items that should be avoided with Risgal?

A: Yes, official labeling specifies that the oral solution formulation of Risgal is incompatible with cola or tea and should not be mixed with these specific beverages.


Q: Is it true that Risgal can cause vivid dreams?

A: Official adverse reaction reports include various sleep disturbances. These documented effects include common issues like insomnia (difficulty sleeping) and somnolence (drowsiness), as well as reports of increased dream activity.


Q: Does Risgal have any effect on sexual function?

A: Yes, official safety data reports adverse reactions that affect sexual function, including sexual dysfunction, decreased libido, ejaculation disorder, and erectile dysfunction. Risgal is also known to elevate prolactin levels (Hyperprolactinemia), which can contribute to these issues.


Q: Will I have withdrawal symptoms if I stop taking Risgal suddenly?

A: Although the drug is not addictive, abrupt cessation of any antipsychotic, including Risgal, has been linked to infrequent reports of acute withdrawal symptoms. These symptoms may include nausea, vomiting, sweating, and insomnia. Dose tapering is generally recommended when discontinuing the medication.


Q: Does Risgal have different side effects for men versus women?

A: While many side effects are common across genders, regulatory information notes that the drug can cause elevated prolactin levels (Hyperprolactinemia). This condition can lead to specific side effects such as galactorrhea (abnormal milk production) in both sexes or gynecomastia (enlargement of breast tissue) in males.


Q: Is it safe to use Risgal during pregnancy or while breastfeeding?

A: Official labeling notes that exposure to Risgal during the third trimester of pregnancy may cause temporary abnormal muscle movements and withdrawal symptoms in the newborn. Due to the active drug being excreted in breast milk, lactation is officially discouraged.


Q: Does Risgal affect my metabolism or energy levels?

A: Yes, official warnings highlight that the drug is associated with significant metabolic changes, including weight gain, high blood sugar, and altered lipid levels. Furthermore, somnolence (drowsiness) is documented as a common side effect, which can affect overall energy levels.


Q: Will I feel better immediately after starting Risgal?

A: According to clinical information, it may take several weeks for symptoms to begin improving. For the long-acting injectable form, the clinical effects of any upward dose adjustment are not expected to be noticeable earlier than three weeks after the injection.


Q: Is hair loss a reported side effect of Risgal?

A: Reports collected from the postmarketing experience of the drug mention instances of hair-related adverse effects, including thinning or loss of hair.

How should Risgal be stored and disposed of?

Official labeling defines precise conditions for storing and disposing of Risgal (risperidone) to maintain its integrity.

Formulation Temperature Requirement Stability Constraint
Oral Tablets Controlled room temperature: 20 C to 25 C (68 F to 77 F). Keep in original container.
Oral Solution Store below 30 C (86 F). Do not refrigerate or freeze. Discard 90 days after opening the bottle.
LAI Suspensions Store refrigerated before preparation. Do not freeze. Must be used immediately or within a short time after mixing.

All formulations must be kept protected from light and stored out of the sight and reach of children. Unused or expired Risgal must be disposed of according to local pharmaceutical waste regulations, typically utilizing official drug take-back programs or the secure mixing procedure for household trash. The medicine must not be placed into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Risgal found in:

A-Z Index: